ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2008
Treatment of adult rhabdoid renal cell carcinoma with sorafenib.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 17 citations in OpenAlex.
- The significance of SMARCB1 in the pathogenesis of renal cell carcinoma with rhabdoid features.Translational oncology · 2021Article
- Multimodal management of locally advanced rhabdoid tumour of the kidney in an adult.BMJ case reports · 2021Article
- Renal cell carcinoma with rhabdoid features: A rare aggressive and fatal variant.Urology case reports · 2020Article
- Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.International journal of clinical and experimental pathology · 2014Article
- Pure malignant rhabdoid tumor of the left kidney in an adult: A case report and review of the literature.Oncology letters · 2013Article
- Chromophobe renal cell carcinoma with rhabdoid differentiation in an adult.Wiener klinische Wochenschrift · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) with rhabdoid features is an uncommon and highly aggressive malignancy. We report a case of adult clear-cell RCC with extensive rhabdoid features treated with the tyrosine kinase inhibitor sorafenib. A review of the literature summarizes important aspects of this malignancy. We discuss clinical and histological findings as well as the patient's response to sorafenib therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.